Message to Patients: How Meridian is addressing COVID-19 at sites nationwide

We’re always taking extra steps to ensure safety as we continue to see patients currently enrolled in clinical trials.

To maintain proper social distancing, Meridian is supporting over-the-phone visits, telemedicine visits, and in-office visits with minimal exposure to others and intensified cleaning processes. Meridian staff disinfect all patient areas immediately after use. In early March, Meridian began restricting work-related travel and in-person meeting attendance.

Without clinical trials, it would not be possible to develop new vaccines and therapies for diseases like COVID-19. Now more than ever, Meridian is prepared to support new tests, vaccines, and medications intended for commercial release.

As a leader in vaccine and infectious disease research, Meridian has always followed processes to protect healthy participants and patients with acute conditions.

If you are in a trial, your participation is crucial to the development of new therapies — Meridian will support you in whatever way possible. If you have questions, please call the site you’re visiting or the Meridian call center: (402) 934-7563 (LA, NE, SD) • (912) 623-2240 (GA, MD, NY, VA).

If you want to join the fight against infectious diseases, we encourage you to talk to your doctor or sign up to be notified when you may be eligible for a study near you.

We appreciate your support as we enter this new era in human health.

Stay safe,
The Meridian Team

Message to Sponsors/CROs: Meridian is supporting clinical trials amid the COVID-19 pandemic

Meridian will remain open to support the research of investigational vaccines, diagnostics, and medications intended for commercial release.

Meridian sites are working with Sponsors and CROs to ensure safety while continuing to enroll patients during the COVID-19 pandemic. We have enrolled more than 25,000 subjects into vaccine and infectious disease clinical trials in the past 20 years, and have always focused on protecting healthy participants and patients with acute conditions.

We’re prepared to address any COVID-19 opportunity and support novel research and development programs. You can expect Meridian to be fully staffed and operational throughout this pandemic, and patients can be confident that every Meridian site is meeting and exceeding safety standards and state-specific regulations.

To maintain proper social distancing, Meridian is supporting over-the-phone visits, telemedicine visits, and in-office visits with minimal exposure to others and intensified cleaning processes. In early March, Meridian began restricting work-related travel and in-person meeting attendance.

As a leading investigative site network for vaccine trials, Meridian has conducted first-in-human studies for emerging diseases. In 2015, the company supported a Phase I study for the Ebola vaccine when the outbreak occurred, and conducted research for Zika virus and anthrax vaccines in the past year.

If you're interested in leveraging Meridian’s network for an infectious disease trial, contact Andrew Kimball, vice president, business development at akimball@mcrmed.com. You can also learn more about Meridian's infectious disease capabilities at mcrmed.com/vaccine.

Stay safe and best regards,
The Meridian Team